Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
100.2 EUR | -1.28% | +0.86% | +7.52% |
Jun. 05 | Mib up at start, DiaSorin good on FDA news | AN |
Jun. 05 | US FDA clears Diasorin's Liaison Plex Yeast Blood Culture Assay | AN |
Sales 2024 * | 1.19B 1.27B | Sales 2025 * | 1.28B 1.37B | Capitalization | 5.41B 5.82B |
---|---|---|---|---|---|
Net income 2024 * | 192M 206M | Net income 2025 * | 216M 232M | EV / Sales 2024 * | 5.15 x |
Net Debt 2024 * | 697M 749M | Net Debt 2025 * | 511M 550M | EV / Sales 2025 * | 4.64 x |
P/E ratio 2024 * |
30.6
x | P/E ratio 2025 * |
26.4
x | Employees | 3,209 |
Yield 2024 * |
0.89% | Yield 2025 * |
1.04% | Free-Float | 37.83% |
Latest transcript on DiaSorin S.p.A.
1 week | +2.64% | ||
Current month | +2.64% | ||
1 month | +8.82% | ||
3 months | +4.69% | ||
6 months | +12.53% | ||
Current year | +8.91% |
Managers | Title | Age | Since |
---|---|---|---|
Carlo Rosa
CEO | Chief Executive Officer | 58 | 97-12-31 |
Director of Finance/CFO | 53 | 10-12-31 | |
Director/Board Member | 61 | 99-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 66 | 22-04-28 | |
Carlo Rosa
CEO | Chief Executive Officer | 58 | 97-12-31 |
Director/Board Member | 61 | 99-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.76% | 15 M€ | -3.61% | ||
0.69% | 5 M€ | +12.55% | ||
0.17% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-06-10 | 100.2 | -1.28% | 9 738 |
24-06-07 | 101.6 | +0.84% | 90,503 |
24-06-06 | 100.7 | +0.20% | 66,829 |
24-06-05 | 100.5 | +1.01% | 74,454 |
24-06-04 | 99.5 | +0.10% | 95,242 |
Real-time Borsa Italiana, June 07, 2024 at 11:44 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.91% | 5.85B | |
-6.76% | 11.98B | |
-5.68% | 8B | |
+28.87% | 5.54B | |
-15.84% | 3.84B | |
+10.70% | 2.66B | |
-60.92% | 2.62B | |
-6.99% | 2.33B | |
-8.85% | 1.78B | |
-6.39% | 1.45B |
- Stock Market
- Equities
- DIA Stock